Effect of Magnesium Supplement in Early Pregnancy After ICSI

NCT ID: NCT03398031

Last Updated: 2018-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-01

Study Completion Date

2018-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Daily supplement of magnesium after biochemical diagnosis of pregnancy in females pregnant after ICSI and through out 1st trimester

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

a fall of magnesium levels at 2-3 weeks of gestation. This drop of magnesium concentration is larger following IVF as compared to spontaneous pregnancies.

so magnesium supplement start after biochemical diagnosis of pregnancy and throughout the 1st trimester

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ICSI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium supplement

90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement

Group Type ACTIVE_COMPARATOR

Magnesium Oxide

Intervention Type DRUG

After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester

placebo

90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet

Group Type PLACEBO_COMPARATOR

Placebo Oral Tablet

Intervention Type DRUG

After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Oxide

After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester

Intervention Type DRUG

Placebo Oral Tablet

After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

magnesium plus tablet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 25\_38 years
* BMI 25\_30

* females pregnant after ICSI after biochemical diagnosis of pregnancy

Exclusion Criteria

* females with poor ovarian reserve and poor responders

* abnormality in uterine cavity detected by hysteroscopic evaluation pre ICSI and not treated
* hydrosalpinx
Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Radwa Rasheedy Ali

lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AinShams university maternity hospital

Cairo, Abbassya, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Radwa R Ali, MD

Role: CONTACT

01283492979 ext. 02002

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ahmed m Abbas, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ashams university

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Kinesiotape on Emesis in Pregnant Women
NCT06625632 NOT_YET_RECRUITING NA